课题基金 / 基金详情

项目摘要

项目成果

Valerian E Kagan的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Myeloid cells are critical component of tumor microenvironment. Under physiological conditions these cells are comprised of mature terminally differentiated cells: polymorphonuclear neutrophils (PMN) and other granulocytes; macrophages (MΦ); and dendritic cells (DCs). In cancer, myeloid compartment is dramatically affected, which is now considered as one of the major immunological hallmarks of cancer. Tumor-bearing (TB) hosts accumulate immunosuppressive MΦ, DCs in cancer are ineffective in induction of potent immune responses. The prominent change in the myeloid compartment in cancer is the expansion of pathologically activated immature myeloid cells with the potent ability to suppress immune responses – myeloid-derived suppressor cells (MDSC). In TB mice, the total population of MDSC consists of three groups of cells: the most abundant (>75%) immature, pathologically activated neutrophils (PMN-MDSC); less abundant (<20%) population of pathologically activated monocytes - (M-MDSC); and small (<5%) population of early myeloid precursors. The current view considers changes in myeloid cells separately. Different mechanisms applied to the different cells. The gap in our knowledge is how these different myeloid cells can interact with each other in tumor-bearing hosts. In this proposal we will test the hypothesis that oxidized lipids may provide bridge between different populations of myeloid cells in cancer and orchestrate their abnormal function. The ultimate goal of this project is not only to better understand the mechanism regulating myeloid cell function in cancer but to develop novel approaches to regulation of immune responses in cancer. To achieve this goal we propose the following specific aims: Specific aim 1. To determine the role of lectin-type oxidized LDL receptor 1 in regulation of PMN-MDSC in cancer patients Specific aim 2. To identify the role of oxidized lipids in the function of PMN-MDSC and DCs.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1039/c8nr04437f
发表时间: 2018-09-27
期刊: Nanoscale
影响因子: 6.7
作者: [Burkert SC , Shurin GV , White DL , He X , Kapralov AA , Kagan VE , Shurin MR , Star A ]
通讯作者: Star A
DOI: 10.1080/2162402x.2023.2192098
发表时间: 2023
期刊: Oncoimmunology
影响因子: 7.2
作者: []
通讯作者:
Therapeutic targeting MDSC-mediated immune suppression in cancer
  • 批准号:
    10540357
  • 项目类别:
  • 资助金额:
    $68.26万
  • 财政年份:
    2021
  • 负责人:
    Valerian E Kagan
  • 依托单位:
Therapeutic targeting MDSC-mediated immune suppression in cancer
  • 批准号:
    10340589
  • 项目类别:
  • 资助金额:
    $71.44万
  • 财政年份:
    2021
  • 负责人:
    Valerian E Kagan
  • 依托单位:
Protein-Oxidized Phospholipid Interactions Determine Epithelial Cell Fate and Asthma Control
Selective Inhibitors of Pro-Ferroptotic Lipoxygenases - Next Generation Radiomitigators
海外基金